Research
Hormonal
Fructose consumption, particularly in large amounts or from added sugars, stimulates hepatic de novo lipogenesis and VLDL-triglyceride secretion, increasing intrahepatic fat and cardiovascular risk, whereas glucose and starch have different, often less adverse, metabolic profiles.
Limit added sugars, particularly those high in fructose (like HFCS and sucrose), as they can promote liver fat accumulation and high triglycerides. While whole fruits are healthy due to fiber, be mindful of concentrated fructose sources. Physical activity can mitigate some of these effects by increasing fructose oxidation.
GoodSupportsHIGH confidence
Compared with dietary starch or glucose, which are only partially metabolized in the liver, fructose is efficiently taken up by hepatocytes, where it stimulates gluconeogenesis and lipogenesis. This is associated with increased intrahepatic fat concentrations, enhanced hepatic VLDL-triglyceride secretion, and impaired suppression of hepatic glucose production.
Why this rating
Supported by metabolic studies and reviews of human trials.
Source
Importance of Carbohydrate Quality: What Does It Mean and How to Measure It?
Vanessa Campos et al. · Journal of Nutrition · 2022
DOI 10.1093/jn/nxac039
narrative_reviewCited 48×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High-quality carbohydrates, defined by high dietary fiber and low added sugar content (e.g., whole grains, pulses, fruit), are associated with lower risks of cardiovascular disease, type 2 diabetes, and all-cause mortality, whereas refined carbohydrates and added sugars are linked to adverse cardiometabolic outcomes.Good
- Empirical metrics such as the 10:1 carbohydrate-to-fiber ratio (and modified versions including added sugar limits) effectively identify high-quality carbohydrate products and are associated with better cardiometabolic health markers, including lower triglycerides and improved insulin sensitivity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →